|Title:||Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry||Authors:||Ghofrani, Hossein-Ardeschir
Gomez Sanchez, Miguel-Angel
Snijder, Repke J
Escribano Subias, Pilar
Mielniczuk, Lisa M
Lange, Tobias J
Helmersen, Douglas S
Barberá, Joan A
Hoeper, Marius M
|Keywords:||Chronic thromboembolic pulmonary hypertension; Clinical practice; Real-world; Registry; Riociguat; Safety;Chronic thromboembolic pulmonary hypertension; Clinical practice; Real-world; Registry; Riociguat; Safety||Issue Date:||2021||Journal Volume:||178||Source:||Respiratory medicine||Abstract:||
The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical practice.
|URI:||https://scholars.lib.ntu.edu.tw/handle/123456789/560671||ISSN:||09546111||DOI:||10.1016/j.rmed.2020.106220||SDG/Keyword:||ambrisentan; bosentan; guanylate cyclase; iloprost; macitentan; prostacyclin; prostanoid; riociguat; treprostinil; pyrazole derivative; pyrimidine derivative; riociguat; adverse event; aged; Article; chronic thromboembolic pulmonary hypertension; clinical practice; clinical trial; cohort analysis; combination drug therapy; disease registry; dizziness; drug safety; dyspnea; faintness; female; heart right ventricle failure; hemoptysis; human; hypotension; lung hemorrhage; major clinical study; male; Medical Dictionary for Regulatory Activities; monotherapy; multicenter study; peripheral edema; phase 3 clinical trial; pneumonia; priority journal; prospective study; pulmonary hypertension; randomized controlled trial; chronic disease; complication; data analysis; lung embolism; middle aged; multicenter study (topic); pulmonary hypertension; randomized controlled trial (topic); recurrent disease; register; safety; time factor; treatment outcome; Aged; Chronic Disease; Data Analysis; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Multicenter Studies as Topic; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic; Recurrence; Registries; Safety; Time Factors; Treatment Outcome
|Appears in Collections:||醫學院附設醫院 (臺大醫院)|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.